Point72 Asset Management’s Lifecore Biomedical LFCR Stock Holding History

Point72 Asset Management’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$276K	Buy	52,520 +27,093	+107%	+$136K	﹤0.01%	3406
2026 Q1	$94.6K	Buy	25,427 +9,771	+62%	+$67.5K	﹤0.01%	3617
2025 Q4	$128K	Buy	+15,656	New	+$116K	﹤0.01%	3709
2023 Q1	–	Sell	-141,446	Closed	-$917K	–	2409
2022 Q4	$917K	Sell	141,446 -44,758	-24%	-$369K	﹤0.01%	1063
2022 Q3	$1.66M	Sell	186,204 -17,496	-9%	-$178K	0.01%	965
2022 Q2	$2.03M	Sell	203,700 -57,856	-22%	-$573K	0.01%	933
2022 Q1	$3.03M	Buy	261,556 +84,537	+48%	+$941K	0.01%	805
2021 Q4	$1.97M	Buy	+177,019	New	+$1.72M	0.01%	825

Other funds holding LFCR

Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return

325 Capital New York $419M AUM 75.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

QOP

Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

Point72 Asset Management's LFCR Position: Q2 2026 in Review

Point72 Asset Management increased its Lifecore Biomedical (LFCR) stake by 107% in Q2 2026, buying an estimated $136K and bringing the position to 52,520 shares worth $276K. The position accounts for ﹤0.01% of the portfolio, ranked #3406.

Point72 Asset Management first reported a position in LFCR in Q4 2021 and has held it in 8 quarters since. The position peaked at $3.03M in Q1 2022. 99 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

Point72 Asset Management held 52,520 shares of Lifecore Biomedical worth $276K as of Q2 2026.
Point72 Asset Management bought 27,093 Lifecore Biomedical shares in Q2 2026, an estimated $136K.
Lifecore Biomedical made up ﹤0.01% of Point72 Asset Management's portfolio in Q2 2026, its #3406 holding.
Point72 Asset Management first reported a position in Lifecore Biomedical in Q4 2021 and has held it in 8 quarters since.
Point72 Asset Management's Lifecore Biomedical position peaked at $3.03M in Q1 2022.
99 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.